Please assess the completion status of the following clinical trial:

Trial Title: Phase II Clinical Study to Assess the Efficacy and Safety of Nemonoxacin Malate in Treating Adult Patients With Community-acquired Pneumonia (CAP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. age of 18\~70, BMI ≥ 18 kg/m2~2. Female patients must avoid pregnancy~3. Patients who are clinically diagnosed with community-acquired pneumonia (CAP)~4. Chest X-ray shows inflammatory exudation or infiltration image.~5. Patients who used antibacterial agents (excluding quinolones) within 72 hours before~6. The patient's disease condition permits oral administration~Exclusion Criteria:~1. Patients who have any of bronchiectasis and pulmonary disease.~2. Hospitalized within 14 days before enrollment~3. Have a history of allergy to any quinolone or fluoroquinolone antibiotic~4. Patients who suffered uncontrolled mental disorders, epilepsy or central nervous system diseases.~5. Renal, liver insufficiency~6. Malabsorption syndrome or other gastrointestinal diseases~7. Immune system diseases,such as a history of human immunodeficiency virus (HIV) infection,neutropenia or malignant tumor in the blood system or a solid organ, or removal of spleen~8. Steroids longterm use, the dose is at least 20mg of prednisone daily~9. Patients under critical condition.~10. Shows significant abnormality of the cardiac conduction system (CCS) or other abnormalities, or prolonged QTc~11. Have a medical history of prolonged QTc, or require concomitant medication of drugs that will lead to prolongation of QTc~12. Patients who received chemotherapy or anti-tumor therapy within 6 months~13. Alcohol abused or drugs banned~14. Patients who used quinolones within two weeks before enrollment~15. Donated more than 500ml of blood within 3 months~16. co-medication of other antibacterial agents required.~17. by investigators judgement,patient who increase the risk to the subjects or interfere with this clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Nemonoxacin 750 mg (Type: ACTIVE_COMPARATOR): Nemonoxacin 750 mg 2 tablets.
- Nemonoxacin 500 mg (Type: ACTIVE_COMPARATOR): Nemonoxacin 500 mg 3 tablets
- Levofloxacin 500 mg (Type: ACTIVE_COMPARATOR): Levofloxacin 500 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).